FDA clears Arvinas breast cancer treatment

Arvinas reports that the FDA has cleared the company’s Investigational New Drug application for ARV-471, an oral estrogen receptor PROTAC® protein degrader, designed for treatment of patients with certain breast cancers

“ARV-471 is our second program in six months to receive IND clearance, and we are pleased to be advancing it into the clinic and progressing Arvinas’ portfolio of PROTAC® protein degraders for the treatment of patients with cancer and other life-threatening diseases,” said John Houston, Ph.D., President and CEO of Arvinas.